A potential MS ‘game changer’ could bring more safety to the table — even against viruses

Immunic’s lead candidate, vidofludimus calcium, has not only shown a “benign” safety and tolerability profile in clinical trials, but also antiviral effects, including against COVID-19.

Moreover, the molecule has anti-inflammatory and neuroprotective features that slow down disease progression, prevent relapses and keep patients physically independent longer, according to Immunic.